

Www.knowledgemagazine.com CONVICE CONTINUE - FOR THE CURIOUS MIND February 2012 issue 21 SCIENCE - HISTORY - NATURE - FOR THE CURIOUS MIND

A GREEK
TRAGEDY
What led to the
Eurozone crisis?

Searching for new life at the foot of the planet p34

Plus: The South Pole, 100 years on - exploring Scott's legacy p40



STINK BIRD
The bird that thinks it's a cow p72



FALL OF THE AZTECSDid their ruler betray his people? p66



IN THE LINE OF FIRE
How to second-guess wildfires p26

Q&A:

Did Picasso steal the Mona Lisa? p85

Undate THE LATEST INTELLIGENCE

• Unlocking the secrets of ancient silks p18 • Were the oceans delivered by comets? p19 • Black Death linked to modern bubonic plaque p20 Does geoengineering offer a cure to the Earth's maladies? p22

► For the latest news visit http://news.bbc.co.uk



New drug could block reactions to anything from pollen to penicillin

ollen, dust and even certain kinds of foods, to name but a few, are all allergens, capable of inducing anything from an irritating rash to a lifethreatening reaction in the susceptible. Current treatments for allergies are often clumsy, tackling the symptoms rather than the cause and occasionally leaving the patient's immune system compromised.

Now biochemists in the US have created a drug designed to halt an allergy in its tracks, preventing the allergen from confusing the human immune system and causing a reaction.

When an allergen such as pollen enters the body, the

immune system recognises it as an invader and produces antibodies in response. These antibodies bind to cells that make up a different part of the immune system, called mast cells. If the allergen enters the body again, it binds with the

involved in the research. "The molecules end up hitting our own tissue. This results in all the symptoms we associate with an allergy."

The solution developed by the biochemists at the University of Notre Dame

HBL steps between the allergen and the immune system, preventing a response

antibodies that are already linked to the mast cells.

"The mast cells release molecules they think will destroy a pathogen - but there is no pathogen," says Basar Bilgiçer of the University of Notre Dame, Indiana, who is

and at Harvard University is a substance they've called a heterobivalent ligand (HBL), which steps between the allergen and the immune system, preventing a response. It binds to the antibodies, thus preventing the allergen from

doing so, meaning the body does not produce the reactive symptoms experienced by allergy-sufferers.

Human bodies contain billions of antibodies, each capable of responding to a specific invader. But HBL binds only to the antibodies produced in response to the allergen, so the rest of the immune system is unaffected.

The scientists carried out their first tests using dinitrophenol – a chemical that has been used as a weight loss drug - as the allergen to be blocked. "The next step would be to do the same thing with penicillin, as it's quite common to have an allergic reaction to it," says Bilgiçer.

Each allergen would need its own HBL to combat it, so it could take some time to develop treatments for several different allergies.